Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population

en faisant une recherche nicox sur leur site ( ça coûte : £8,992.00 )
il y avait ceci :

Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population (Datamonitor)

Market: Healthcare and Medical
Published Date: 04/12/2009
Report Title: Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population
Table of Contents: View Table of Contents
Report Type: Market Report
Number of Pages: 205
Introduction

The report expects osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.

Scope

*Snapshot of the osteoarthritis market based on a survey of 180 rheumatologists/primary care physicians, with views from key opinion leader interviews

*Analysis of osteoarthritis epidemiology, with future projections of prevalence and patient numbers to 2020

*Overview of treatment options at the class and molecule level, as well as treatment outcome analysis

*Assessment of treatment satisfaction, unmet needs and physicians' awareness of key pipeline therapies

Highlights

The estimated diagnosis rate of 55% reflects a lack of treatment-seeking by mild sufferers of the disease, who often resort to self-medication. This equates to nearly 37 million undiagnosed patients in 2009 and with a predicted rise in osteoarthritis numbers this is a market with growth potential.

Pain-relieving drugs, particularly, oral non-steroidal anti-inflammatory drugs (NSAIDs) are the foundation of pharmacological therapy in osteoarthritis. Physicians continue to be concerned over NSAID toxicity, with three-quarters of severe patients who are receiving NSAIDs currently co-prescribed a gastroprotectant.

Physicians are generally unsatisfied with current osteoarthritis pharmacological treatments. A clear need for alternative drugs exists to treat this prevalent condition. 41% of physicians ranked disease modifying osteoarthritis drugs (DMOADs) as the highest unmet need, but the majority of physicians estimate that DMOADs are 8 years from the market.

Reasons to Purchase

*Understand current therapy trends for the major drug classes used in osteoarthritis split by disease severity and assess unmet needs in the disease

*Validate new product forecasting based on diagnosis rates and treatment by patient segmentation and drug class

*Use the interactive Excel model of treatment trees and patient numbers to estimate the osteoarthritis population in each of the seven major markets

simis a écrit:

en faisant une recherche nicox sur leur site ( ça coûte : £8,992.00 )
il y avait ceci :

Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population (Datamonitor)

Market: Healthcare and Medical
Published Date: 04/12/2009
Report Title: Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population
Table of Contents: View Table of Contents
Report Type: Market Report
Number of Pages: 205
Introduction

The report expects osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.

Scope

*Snapshot of the osteoarthritis market based on a survey of 180 rheumatologists/primary care physicians, with views from key opinion leader interviews

*Analysis of osteoarthritis epidemiology, with future projections of prevalence and patient numbers to 2020

*Overview of treatment options at the class and molecule level, as well as treatment outcome analysis

*Assessment of treatment satisfaction, unmet needs and physicians' awareness of key pipeline therapies

Highlights

The estimated diagnosis rate of 55% reflects a lack of treatment-seeking by mild sufferers of the disease, who often resort to self-medication. This equates to nearly 37 million undiagnosed patients in 2009 and with a predicted rise in osteoarthritis numbers this is a market with growth potential.

Pain-relieving drugs, particularly, oral non-steroidal anti-inflammatory drugs (NSAIDs) are the foundation of pharmacological therapy in osteoarthritis. Physicians continue to be concerned over NSAID toxicity, with three-quarters of severe patients who are receiving NSAIDs currently co-prescribed a gastroprotectant.

Physicians are generally unsatisfied with current osteoarthritis pharmacological treatments. A clear need for alternative drugs exists to treat this prevalent condition. 41% of physicians ranked disease modifying osteoarthritis drugs (DMOADs) as the highest unmet need, but the majority of physicians estimate that DMOADs are 8 years from the market.

Reasons to Purchase

*Understand current therapy trends for the major drug classes used in osteoarthritis split by disease severity and assess unmet needs in the disease

*Validate new product forecasting based on diagnosis rates and treatment by patient segmentation and drug class

*Use the interactive Excel model of treatment trees and patient numbers to estimate the osteoarthritis population in each of the seven major markets

Molto interessante ...

Se qualcuno potesse avere accesso al documento e renderlo disponibile ...


Domani allora comunicheranno i risultati delll'AK ... e speriamo di non avere sorprese negative !

Grazie SIMIS ...

Merci MariNO

"Physicians are generally unsatisfied with current osteoarthritis
pharmacological treatments. A clear need for alternative drugs exists
to treat this prevalent condition." =